Abstract
Asenapine (ASE), an atypical antipsychotic drug used in the treatment of schizophrenia, induces Fos expression in forebrain. Effect of ASE on activity of basal nucleus of Meynert (NBM) cells, a part of the striatal-cortical circuits, was studied. We were also interested to reveal whether a chronic unpredictable variable mild stress (CMS) preconditioning might affect the ASE impact. Rats were divided into as follows: controls-vehicle, controls-ASE, stressed-vehicle and stressed-ASE groups. CMS included restrain, social isolation, crowding, swimming and cold applied for 21 days. On the 22nd day, rats were subcutaneously injected with ASE (0.3 mg/kg) or vehicle (saline 300 μl/rat), 90 min prior euthanizing. After transcardial fixation, brains were cut into 30 μm thick coronal sections. Fos protein presence, as indicator of cell activity, was detected by ABC immunohistochemistry. Hypocretin (Hcrt) and melanin-concentrating hormone (MCH) containing cells were visualized with fluorescent dyes. ASE induced significant increase in Fos expression in NBM in both controls and CMS preconditioned rats in comparison with the related vehicle-treated controls. CMS preconditioning, however, significantly lowered the Fos response to ASE in NBM. ...Continue Reading
References
Jan 1, 1990·Pharmacology & Therapeutics·P Willner
Sep 1, 1989·Journal of Neuroscience Methods·M Dragunow, R Faull
Jan 1, 1989·Neuroscience·A LysakowskiL B Hersh
Sep 22, 1983·Nature·H KawauchiB I Baker
Feb 1, 1997·Neuroscience·L HeimerJ de Olmos
Feb 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·L de LeceaJ G Sutcliffe
Mar 10, 1998·Cell·T SakuraiM Yanagisawa
Jun 19, 1998·Brain Research·I UsudaT Chiba
Aug 26, 1998·Journal of Chemical Neuroanatomy·J RodrigoR Martínez-Murillo
Mar 26, 1999·Trends in Neurosciences·M Sarter, J P Bruno
Mar 17, 2000·Brain Research. Brain Research Reviews·L Heimer
Sep 30, 2000·Brain Research·Y Q ZhangJ Mei
Nov 29, 2002·Psychopharmacology·A V TerryS P Mahadik
Sep 11, 2003·BMC Neuroscience·Laure VerretPierre-Hervé Luppi
Sep 30, 2003·The American Journal of Psychiatry·Lennart Heimer
Jan 11, 2005·Current Pharmaceutical Design·P J Mitchell, P H Redfern
Feb 8, 2005·Nature Neuroscience·J AmatS F Maier
May 4, 2005·Biological Psychiatry·Vicente MartinezMartin Sarter
Aug 25, 2007·Brain Structure & Function·K W S Ashwell, G Paxinos
Mar 1, 2008·Journal of Psychopharmacology·M ShahidE H F Wong
Apr 18, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mei HuangHerbert Y Meltzer
Aug 23, 2008·Journal of Psychopharmacology·F I TaraziM Shahid
Nov 18, 2008·Neuroscience Letters·Núria Boix-TrelisMargarita Martí-Nicolovius
Aug 12, 2010·Journal of Psychopharmacology·Hugh M MarstonMohammed Shahid
Aug 28, 2012·Neuroscience·G D PetrovichC J Reppucci
Nov 7, 2012·Endocrine Regulations·Z MajercikovaA Kiss
Jan 10, 2013·PloS One·Kewir D NyuykiStefan O Reber
Sep 17, 2013·Neuroscience and Biobehavioral Reviews·James GratwickeMarjan Jahanshahi
Jun 7, 2014·Frontiers in Neuroanatomy·Rege S Papp, Miklós Palkovits
Aug 31, 2014·Brain Research Bulletin·Zuzana MajercikovaAlexander Kiss